AMVUTTRA's ATTR-CM launch propels Alnylam's Q2 revenue 67% higher to $1.29B, swinging to a $164.5M net profit
ALNY is trading near its 52-week low of $262.21 (8.5% below the low).
Summary
Powered by the AMVUTTRA ATTR-CM launch, Q2 2026 revenue surged 67% to $1.29B, swinging to net income of $164.5M. Pipeline advances and a strong cash position reinforce the growth trajectory.
Key Events · Earnings and Guidance · ALNY
-
Q2 Revenue Surges 67% to $1.29B
Total revenues reached $1.29 billion, up from $773.7 million in Q2 2025, driven by AMVUTTRA's ATTR-CM launch. Net product revenues were $1.17 billion, with AMVUTTRA contributing $1.01 billion globally.
-
Net Income Swings to $164.5M Profit
Alnylam reported Q2 net income of $164.5 million, or $1.21 per diluted share, compared to a net loss of $72.2 million in the prior-year period. Six-month net income was $370.5 million.
-
AMVUTTRA ATTR-CM Launch Drives TTR Franchise
AMVUTTRA global net product revenues more than doubled to $1.01 billion, with U.S. sales of $809.1 million. The total TTR franchise (AMVUTTRA + ONPATTRO) generated $1.03 billion, up 89% year-over-year.
-
Pipeline Advances: Mivelsiran and Cemdisiran
Enrollment completed in the Phase 2 cAPPricorn-1 trial of mivelsiran in CAA; a Phase 2 trial in Down syndrome-associated AD was initiated. Regeneron's NDA for cemdisiran in gMG was accepted with Priority Review and a November 2026 PDUFA date.
Analysis · ALNY · Life Sciences
A standout quarter was driven by the ongoing U.S. launch of AMVUTTRA for ATTR cardiomyopathy, pushing total revenues up 67% year-over-year to $1.29 billion. Global net product revenue for AMVUTTRA alone reached $1.01 billion, more than doubling from a year ago. The top-line surge flipped the bottom line to a net income of $164.5 million from a loss of $72.2 million in the prior-year quarter, and six-month net income hit $370.5 million. The balance sheet remains robust, with $3.31 billion in cash and marketable securities. On the pipeline front, enrollment was completed in the Phase 2 cAPPricorn-1 trial of mivelsiran in cerebral amyloid angiopathy, and a Phase 2 trial in Down syndrome-associated Alzheimer's was initiated. Separately, Regeneron's NDA for cemdisiran in generalized myasthenia gravis was accepted with Priority Review and a November 2026 target action date. With the stock trading near its 52-week low, the positive earnings surprise may carry amplified impact.
At the time of this filing, ALNY was trading at $239.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3B. The 52-week trading range was $262.21 to $495.55. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.